Geode Capital Management LLC Purchases 19,095 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

Geode Capital Management LLC raised its position in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 0.8% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 2,309,778 shares of the company’s stock after buying an additional 19,095 shares during the quarter. Geode Capital Management LLC’s holdings in Compass Therapeutics were worth $4,251,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its position in shares of Compass Therapeutics by 12.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock worth $284,000 after acquiring an additional 31,433 shares in the last quarter. Barclays PLC boosted its holdings in shares of Compass Therapeutics by 195.4% in the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after purchasing an additional 112,614 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Compass Therapeutics by 99.7% in the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after purchasing an additional 70,200 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Compass Therapeutics by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after purchasing an additional 12,315 shares during the last quarter. Finally, Ground Swell Capital LLC acquired a new position in shares of Compass Therapeutics during the 2nd quarter worth $124,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a research report on Monday, September 16th. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. D. Boral Capital began coverage on shares of Compass Therapeutics in a research note on Monday, December 23rd. They issued a “buy” rating and a $32.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research note on Monday, November 11th. Finally, Leerink Partners cut Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $5.00 to $4.00 in a research note on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Compass Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $11.80.

Compass Therapeutics Price Performance

CMPX opened at $1.56 on Monday. Compass Therapeutics, Inc. has a fifty-two week low of $0.77 and a fifty-two week high of $2.34. The company’s 50 day moving average price is $1.57 and its two-hundred day moving average price is $1.43. The firm has a market capitalization of $214.64 million, a price-to-earnings ratio of -4.22 and a beta of 0.89.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. As a group, equities research analysts predict that Compass Therapeutics, Inc. will post -0.35 EPS for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.